Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Human papillomavirus (HPV)
SAGE documentation
Scientific publications
2022
2010
Clear all
Type of publications
NITAG documentation
(98)
Reports
(1)
SAGE documentation
(18)
Scientific publications
(8)
Systematic reviews (SYSVAC)
(567)
Topics
Background paper
(1)
Evidence to recommendation table
(1)
GRADE table
(3)
Position paper
(11)
SAGE background document
(2)
Available to download in languages
English (EN)
(25)
French (FR)
(4)
Portugese (PT)
(1)
Russian (RU)
(1)
Regions
Africa
(1)
Americas
(1)
Eastern Mediterranean
(1)
Europe
(1)
South-East Asia
(1)
Western Pacific
(2)
Countries
Diseases
COVID-19
(17)
Human papillomavirus (HPV)
(9)
Cholera
(1)
Haemophilus influenzae type B
(4)
Hepatitis A
(5)
Influenza
(2)
Malaria
(6)
Measles
(1)
Meningococcal disease
(1)
Mpox // Monkeypox
(4)
Mumps
(1)
Rabies
(1)
Rotavirus
(1)
Rubella
(1)
Vaccine topics
Target population
Publication date
2022
(19)
2010
(7)
2023
(2)
2021
(6)
2020
(3)
2019
(1)
2018
(1)
2017
(13)
2015
(2)
2014
(2)
2013
(2)
2012
(1)
2011
(1)
2009
(2)
2008
(1)
26 results found
2022
∙
SAGE
Should an off-label , permissive one-dose HPV vaccine schedule for use in routine and/or multi-age cohort (MAC) catch up strategies be recommended?
2022
∙
SAGE
Human papillomavirus vaccines: WHO position paper, December 2022
2022
∙
Christoph Steffen, Louise Henaff, Shalini Desai, Noni MacDonald, Anna-Lea Kahn, Christopher Morgan, Folake Olayinka, Ruth Faden
COVID-19 Vaccine Policy Development in a Sample of 44 Countries- Key Findings from a December 2021 Survey of National Immunization Technical Advisory Groups (NITAGs)
2022
∙
SAGE
Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19
2022
∙
SAGE
Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™)
2022
∙
SAGE
Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19
2022
∙
SAGE
WHO interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2 - 18 August 2022
2022
∙
SAGE
Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine
2022
∙
SAGE
Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm
2022
∙
SAGE
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register